My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.46 +0.09 (+0.49%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Why Shares of Innate Pharma Jumped Thursday ↗

June 08, 2023

The company's collaboration agreement with Sanofi could soon pay off.

Via The Motley Fool

FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq ↗

May 19, 2023

The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to

Via Benzinga

Takeda Moves Out From Licensing Agreement With Theravance Biopharma ↗

May 11, 2023

In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...

Via Benzinga

Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues ↗

May 11, 2023

Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its

Via Benzinga

Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More ↗

April 25, 2023

Equilibria Strengthens Women's Wellness With New CSO

Via Benzinga

Zoetis Stock Shows Rising Relative Strength Upgrades ↗

February 17, 2023

Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Via Investor's Business Daily

Earnings Scheduled For May 11, 2023 ↗

May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...

Via Benzinga

Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday ↗

April 25, 2023

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

Via The Motley Fool

This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗

April 25, 2023

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

Via The Motley Fool

United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗

April 21, 2023

The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 11, 2023

We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday!

Via InvestorPlace

Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens ↗

April 10, 2023

Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday

Via Investor's Business Daily

Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal ↗

April 08, 2023

Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...

Via Talk Markets

The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat ↗

April 05, 2023

Millions of people are scrambling to get their ADHD medication. Here's why.

Via Investor's Business Daily

Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

April 04, 2023

B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell...

Via Benzinga

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗

March 27, 2023

Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.

Via Investor's Business Daily

Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million ↗

March 25, 2023

HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product...

Via Talk Markets

Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says ↗

March 20, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗

March 16, 2023

Via Benzinga

Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies ↗

March 15, 2023

Via Benzinga

Should You Give Up on Novavax? ↗

March 03, 2023

After a spectacular 2020 performance, Novavax's shares have plummeted.

Via The Motley Fool

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing ↗

March 02, 2023

The FDA made a bold move in the CRISPR gene-editing realm.

Via Investor's Business Daily

2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now ↗

February 28, 2023

These two high-yield dividend stocks are trading at bargain-basement prices.

Via The Motley Fool

Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients ↗

February 21, 2023

Via Benzinga

Is This the Telltale Sign to Sell Novavax Stock? ↗

February 14, 2023

You won't find Novavax's latest bad news trumpeted in a press release.

Via The Motley Fool

NeurAxis: Should You Buy This IPO? ↗

February 08, 2023

As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.

Via Talk Markets

NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution ↗

February 06, 2023

As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.

Via Talk Markets

Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged ↗

February 02, 2023

Via Benzinga

7 Sorry Dividend Stocks to Sell in February Before It’s Too Late ↗

January 30, 2023

These dividend stocks to sell have weak underlying fundamentals, offering little upside potential ahead for investors.

Via InvestorPlace

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.